Geron Future Growth

NasdaqGS:GERN - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	562	116	57	100	7
12/31/2025	301	-50	-93	-85	9
12/31/2024	89	-167	-115	-198	9
9/30/2024	29	-201	-216	-216	N/A
6/30/2024	1	-220	-209	-208	N/A
3/31/2024	1	-201	-185	-184	N/A
12/31/2023	0	-184	-169	-168	N/A
9/30/2023	0	-175	-163	-162	N/A
6/30/2023	0	-171	-142	-141	N/A
3/31/2023	0	-150	-141	-140	N/A
12/31/2022	1	-142	-128	-127	N/A
9/30/2022	2	-131	-115	-114	N/A
6/30/2022	1	-117	-108	-108	N/A
3/31/2022	1	-118	-97	-97	N/A
12/31/2021	1	-116	-96	-96	N/A
9/30/2021	0	-108	-86	-86	N/A
6/30/2021	0	-101	-79	-79	N/A
3/31/2021	0	-87	-73	-73	N/A
12/31/2020	0	-76	-67	-67	N/A
9/30/2020	0	-81	-65	-64	N/A
6/30/2020	0	-76	-62	-61	N/A
3/31/2020	0	-75	-58	-57	N/A
12/31/2019	0	-69	-44	-44	N/A
9/30/2019	1	-47	-37	-36	N/A
6/30/2019	1	-37	-31	-31	N/A
3/31/2019	1	-30	-26	-26	N/A
12/31/2018	1	-27	-21	-21	N/A
9/30/2018	1	-27	-22	-22	N/A
6/30/2018	1	-28	N/A	-21	N/A
3/31/2018	1	-28	N/A	-21	N/A
12/31/2017	1	-28	N/A	-21	N/A
9/30/2017	1	-29	N/A	-17	N/A
6/30/2017	6	-26	N/A	-19	N/A
3/31/2017	6	-28	N/A	-20	N/A
12/31/2016	6	-30	N/A	-18	N/A
9/30/2016	6	-30	N/A	-23	N/A
6/30/2016	37	1	N/A	-21	N/A
3/31/2016	37	1	N/A	-22	N/A
12/31/2015	36	0	N/A	-24	N/A
9/30/2015	36	0	N/A	10	N/A
6/30/2015	1	-37	N/A	10	N/A
3/31/2015	1	-37	N/A	11	N/A
12/31/2014	1	-36	N/A	9	N/A
9/30/2014	1	-36	N/A	-26	N/A
6/30/2014	1	-35	N/A	-27	N/A
3/31/2014	1	-35	N/A	-30	N/A
12/31/2013	1	-38	N/A	-37	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GERN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: GERN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: GERN is expected to become profitable in the next 3 years.

Revenue vs Market: GERN's revenue (51.8% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: GERN's revenue (51.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if GERN's Return on Equity is forecast to be high in 3 years time

Geron Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Consensus revenue estimates increase by 55%

Consensus revenue estimates decrease by 16%

Price target increased by 7.0% to US$5.08

Consensus revenue estimates decrease by 13%

Consensus revenue estimates decrease by 21%, EPS upgraded

Forecast to breakeven in 2026

Recent updates

Consensus revenue estimates increase by 55%

Geron Corporation Appoints Joseph Eid as Executive Vice President, Research and Development

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Geron: A Post Earnings And Funding Announcement Assessment

Geron Corporation Announces New Data to Be Present at Upcoming ASH Annual Meeting Highlighting Potential of RYTELO (Imetelstat) in Myeloid Hematologic Malignancies

Is Geron (NASDAQ:GERN) Using Too Much Debt?

Geron Corporation to Report Q3, 2024 Results on Nov 07, 2024

Geron's Rytelo Gains Traction Despite Competitive Pressures (Rating Upgrade)

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Geron: Probabilistic And Modest Estimate Of Pricing For A Likely Acquisition

Geron Corporation Announces Chief Commercial Officer to Depart, Effective August 31, 2024

Geron Corporation to Report Q2, 2024 Results on Aug 08, 2024

Does Geron (NASDAQ:GERN) Have A Healthy Balance Sheet?

Executive VP & COO notifies of intention to sell stock

Chairman of the Board notifies of intention to sell stock

Geron: Innovative Rytelo Enters A Challenging MDS Market

Geron Corporation Announces FDA Approval of RYTELO (imetelstat) for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia

Why We Think Geron Corporation's (NASDAQ:GERN) CEO Compensation Is Not Excessive At All

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Geron Corporation to Report Q1, 2024 Results on May 02, 2024

Consensus revenue estimates decrease by 16%

Geron Corporation, Annual General Meeting, May 09, 2024

Geron Corporation has completed a Follow-on Equity Offering in the amount of $149.999995 million.

Price target increased by 7.0% to US$5.08

Consensus revenue estimates decrease by 13%

New major risk - Share price stability

Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy

Geron Corporation Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS

Consensus revenue estimates decrease by 21%, EPS upgraded

Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Geron Corporation to Report Q4, 2023 Results on Feb 28, 2024

New minor risk - Share price stability

Forecast to breakeven in 2026

Geron Announces 50% Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis

Geron Announces Publication in the Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS

Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors

Consensus revenue estimates increase by 76%

Geron Corporation has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Geron Corporation to Report Q3, 2023 Results on Nov 02, 2023

Geron Corporation Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS

Geron Corporation Announces Chief Financial Officer Changes, Effective September 25, 2023

Is Geron (NASDAQ:GERN) A Risky Investment?

Geron Corporation Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS

Consensus revenue estimates fall by 14%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Geron Corporation to Report Q2, 2023 Results on Aug 03, 2023

Geron Corporation Announces U.S. Expanded Access Protocol for Imetelstat in Lower Risk MDS

Geron Corporation Announces Submission of New Drug Application to FDA for First-In-Class Telomerase Inhibitor Imetelstat

Geron Corporation Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDS

Geron Corporation Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients

Consensus revenue estimates increase by 29%

Geron Corporation Announces Board Changes

Consensus revenue estimates decrease by 48%, EPS upgraded

Geron Corporation Announces Five Abstracts Related to Imetelstat Accepts at European Hematology Association Annual Meeting

Is Geron (NASDAQ:GERN) Using Debt Sensibly?

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Geron Corporation to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Chairman of the Board notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Geron Corporation has completed a Follow-on Equity Offering in the amount of $198.121928 million.

Geron Corporation has completed a Follow-on Equity Offering in the amount of $198.121928 million.

Geron Corporation Announces Positive Top-Line Results from IMerge Phase 3 Trial of Imetelstat in Lower Risk MDS

Price target increased to US$4.50

An Intrinsic Calculation For Geron Corporation (NASDAQ:GERN) Suggests It's 46% Undervalued

Geron Corporation Reports Oral Presentation at ASH Annual Meeting Highlighting Continuous Long-Term Transfusion Independence with Imetelstat Treatment in Lower Risk MDS Patients

Insufficient new directors